Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Cellectis S.A.NASDAQ: CLLS

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt rises 200.8% from a year ago

Short-term debt stood at $15.16M at the end of Q1 FY2026, up 200.8% from a year earlier and down 16.5% from the prior quarter. Over 3 fiscal years it compounded at +54.0% a year.

Context

  • Short-term debt amounted to 5.2% of total assets at the end of Q1 FY2026, up 3.9 pp from a year earlier.
  • Short-term debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term debt keeps rising in the next quarterly balance sheet after a +200.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.16M-16.5% QoQ
Last fiscal yearDec 2025
$18.16M+275.1% YoY
Year agoMar 2025
$5.04M+200.8% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+200.8%——
1 year+275.1%——
3-year CAGR+54.0%——
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
18.16M USD
Year-over-year change
+275.1%
4-year CAGR
+68.6%

Short-term Debt vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +200.8% is the 2nd highest of 4, against a peer median of +92.3%.
  • Short-term debt amounts to 5.2% of total assets for CLLS, versus a peer median of 0.0%.
CLLS Competitors
Short-term Debt for CLLS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALDXAldeyra Therapeutics, Inc.Mar 2026$15.3M USD+5892.0%+155.7%23.0%
CLLSCellectis S.A.Mar 2026$15.16M USD+200.8%+54.0%5.2%
DBVTDBV Technologies S.A.Mar 2026$11.2M USD+92.3%+143.2%4.2%
ANROAlto Neuroscience, Inc.Mar 2026$2.14M USD—+27.4%0.8%
LRMRLarimar Therapeutics, Inc.Mar 2026$1.06M USD-3.5%—0.5%
DRTSAlpha Tau Medical Ltd.Mar 2026$0 USD——0.0%
SLNSilence Therapeutics plcMar 2026$0 USD——0.0%
AMRNAmarin Corporation plcMar 2026$0 USD——0.0%
ACIUAC Immune S.A.Mar 2026CHF 0 CHF——0.0%
KRROKorro Bio, Inc.Mar 2026$0 USD——0.0%
MREOMereo BioPharma Group plcMar 2026$0 USD——0.0%
Peer median (excluding CLLS) —+92.3%+143.2%0.0%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents185.64M89.79M136.71M143.25M63.58M
Short-term Investments499K7.91M67.11M117.06M145.08M
Net Receivables31.07M17.57M23.13M23.04M25.32M
Inventory00000
Other Current Assets50K22.31M345K298K329K
Total Current Assets225.43M143.81M233.01M287.07M236.24M
Property, Plant & Equipment (Net)148.27M107.9M92.74M75.86M62.45M
Goodwill00000
Intangible Assets1.85M718K672K1.12M535K
Long-term Investments6.52M8.79M7.85M7.52M5.09M
Tax Assets000382K382K
Other Non-current Assets3K0(1K)11.6M20.03M
Total Non-current Assets156.65M117.41M101.27M96.48M88.48M
Total Assets382.08M261.22M334.27M383.54M324.72M
Account Payables23.76M21.46M19.07M18.66M17.28M
Short-term Debt2.25M4.97M5.16M4.84M18.16M
Tax Payables71K3.06M016K0
Deferred Revenue301K59K110.33M112.16M96.8M
Other Current Liabilities2.16M16.16M2.72M13.37M13.51M
Total Current Liabilities49.35M63M155.14M166.27M145.75M
Long-term Debt18.77M13.57M28.44M43.99M74.01M
Deferred Tax Liabilities00158K00
Deferred Revenue (Non-current)00000
Other Non-current Liabilities5.96M9.35M22.88M17.02M1.33M
Total Non-current Liabilities96.25M72.28M94.43M95.25M103.07M
Total Liabilities145.6M135.28M249.58M252.51M248.82M
Common Stock2.95M2.96M4.37M5.89M5.9M
Retained Earnings(698.33M)(439.5M)(405.77M)(329.61M)(334.13M)
Accumulated OCI(18.02M)(28.61M)(36.69M)(39.54M)(33.32M)
Other Stockholders Equity(1K)01K00
Minority Interest15.18M7.97M000
Total Equity236.47M125.94M84.7M131.03M75.9M
Total Debt100.87M75.77M85.06M91.46M119.9M
Net Debt(84.77M)(14.02M)(51.65M)(51.79M)56.32M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.